Acceleron Pharma Inc. (NYSE:XLRN)‘s stock had its “outperform” rating reiterated by analysts at Credit Suisse Group in a report issued on Tuesday. They presently have a $51.00 price objective on the stock, up from their prior price objective of $35.00.

ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/14/credit-suisse-group-reiterates-outperform-rating-for-acceleron-pharma-inc-xlrn.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.